What is the approximate medical insurance reimbursement ratio of ibrutinib/ibrutinib in 2025?

As of 2025, Ibrutinib (Ibrutinib), as a targeted drug widely used to treat hematological malignancies, has been included in the Category B scope of China’s National Basic Medical Insurance Drug Catalogue, and medical insurance reimbursement policies have been implemented in many provinces and cities. This inclusion in medical insurance has greatly reduced the financial burden on patients and made this originally expensive new targeted drug more accessible. According to public information, the original product specification of ibrutinib is 140 mg × 90 tablets, and the market price is around 10,000 yuan. However, after reimbursement through medical insurance, the actual out-of-pocket cost of the patient can be significantly reduced.

The proportion of medical insurance reimbursement in 2025 will vary depending on the region, type of medical insurance and designated medical institutions, but the general range is between 60% and 80%. In terms of the prerequisites for reimbursement, the medical insurance clearly stipulates the applicable groups: first, patients with mantle cell lymphoma (MCL) who have received at least one treatment in the past; second, patients diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); third, patients diagnosed with Waldenstrom's macroglobulinemia (WM), and must comply with the standard usage recommended by the drug instructions. In other words, when using ibrutinib, patients not only need to have an accurate diagnosis, but also have to have a prescription issued by a doctor at a designated hospital and settle the bill within the medical insurance network system in order to enjoy the corresponding reimbursement policy.

The dynamic adjustment of the medical insurance catalog also brings hope to patients. In recent years, the National Medical Security Administration has continued to promote price reductions for innovative drugs through the drug negotiation mechanism. Ibrutinib has participated in many negotiations and successfully reduced its price and was included in medical insurance, making its originally high price gradually return to rationality. It is worth noting that medical insurance reimbursement usually has a cap line on a quarterly or annual basis, and is subject to conditions such as self-payment first and settlement later, and restrictions on medication types. Therefore, patients should consult a doctor or medical insurance window in detail during the actual medical treatment and reimbursement process to obtain the most accurate policy support.

Reference materials:https://www.imbruvica.com/